Clinical Trial Liability Insurance in New York

New York at a glance

Primary regulator

New York State Department of Financial Services

Oversees insurer licensing and policy forms for coverage written in the state.

Governing research statute

Public Health Law Article 24-A

Adds state-specific consent and review duties beyond the federal Common Rule.

Institutional landscape

Dense academic medical center cluster in New York City and the Hudson Valley

Drives frequent overlap between institutional self-insurance and sponsor trial coverage.

IRB practice

Common use of central and reliance IRB arrangements

A single IRB of record can oversee a multi-site New York protocol, concentrating review risk.

Public Health Law Article 24-A and its added duties

New York codified human-subject protections in Public Health Law Article 24-A, which sets consent and review obligations for research conducted in the state in addition to federal Common Rule and FDA requirements. Sites operating solely under an out-of-state sponsor's federally compliant protocol should still confirm the protocol satisfies Article 24-A's own consent-content and review requirements, since a federally adequate consent form is not automatically sufficient under state law.

Academic medical center indemnification layering

New York City and the Hudson Valley host a dense cluster of academic medical centers running investigator-initiated and sponsor-funded trials simultaneously, and many of these institutions maintain their own self-insurance or indemnification programs for faculty investigators. A sponsor's clinical trial policy and an institution's self-insured retention can create gaps or overlaps depending on how the site agreement allocates responsibility for participant injury versus institutional negligence, so the two programs need to be read together rather than assumed to stack cleanly.

IRB landscape and multi-site review

Large New York systems frequently rely on central or reliance IRB arrangements that let one institutional review board oversee a multi-site protocol spanning several hospitals, which speeds enrollment but also means a single review lapse can expose every participating site. Confirming which entity holds IRB-of-record status, and how that entity's liability exposure is addressed contractually, is a routine underwriting question in New York specifically because reliance arrangements are so common here.

Building a program around the state's research footprint

A New York clinical trial program typically pairs trial liability with products/completed-operations for the investigational product, medical professional liability for treating investigators, and cyber coverage addressing both HIPAA and New York's SHIELD Act data-security obligations for participant records. Article 24-A's requirements and reliance-IRB practices evolve, so confirm current consent and review standards with counsel before setting protocol-specific limits.

Who we write this for in New York

Clinical trial liability FAQs for New York